GLPG1837

Small molecule CFTR potentiator

Phase of research

Pre-clinical

How it helps

Restore CFTR Function

General information

GLPG1837 is an experimental substance used in studies and not yet available as a human pharmaceutical. In relation to cystic fibrosis, our AIM tool found the data that GLPG1837 can help potentiate G178R-, G551D-, S549N- and R117H-CFTR channels and also corrector-rescued F508del-CFTR.

GLPG1837 on PubChem

Synonyms

N/A

Marketed as

N/A

Dietary sources

N/A

C₁₆H₂₀N₄O₃S

Drug-Mutation Relation

results for D1152H / F508del

See all data on GLPG1837

Treats

Mutation	Link	Tested on	Impact factor	Notes
F508del	Identification and Characterization of Novel CFTR Potentiators	human cell cultures	3.85	In combination with F508del correction.

Does not treat

Mutation	Link	Tested on	Impact factor	Notes